Search the Newsreel

NeuroSense Therapeutics (NRSN) revises Capital on Demand share sales deal

NeuroSense Therapeutics has amended its Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC, updating the referenced registration statement to a new Form F-3 (File No. 333-293060), which became effective on July 31, 2026. Under the revised agreement, the company can offer and …

NeuroSense Therapeutics Ltd. Revenue Breakdown – NASDAQ:NRSNW

This article provides a brief overview of NeuroSense Therapeutics Ltd. (NASDAQ: NRSNW) financial information. It indicates that the market was closed at the time of viewing and that no trades were made, with details on financial statements, dividends, earnings, and segments available for further …

NeuroSense Therapeutics (NRSN) sets $150M shelf and $3.8M ATM share plan

NeuroSense Therapeutics has filed a shelf registration to offer up to $150 million in various securities and a related at-the-market (ATM) program for up to $3.8 million in ordinary shares. The company, focused on neurodegenerative diseases like ALS, reported positive Phase 2b data for …

Price to earnings forward of NeuroSense Therapeutics Ltd. – BOATS:NRSNW

This article provides a brief snapshot of the "Price to earnings forward" metric for NeuroSense Therapeutics Ltd. (NRSNW) as listed on the Blue Ocean Alternative Trade System (BOATS). It notes that there are no current trades and displays the period, value, and change for …

Neurosense Therapeutics is a buy, this analyst says

Roth Capital Partners analyst Boobalan Pachaiyappan has reaffirmed his "Buy" rating and $3.00 price target for Neurosense Therapeutics (NASDAQ:NRSN), citing reduced regulatory uncertainty for its ALS drug candidate, PrimeC, in Canada. Despite a recent stock dip, the company has aligned with Health Canada for …

Neurosense Therapeutics Ltd. Revenue Breakdown – FWB:H1Z

This article provides an overview of Neurosense Therapeutics Ltd. (H1Z) listed on the Frankfurt Stock Exchange. It highlights the availability of financial data, segments, and other fundamental statistics for the company on the TradingView platform. The content focuses on navigating the financial information for …

Neurosense Therapeutics Ltd (NRSN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey

This article provides a brief overview of Neurosense Therapeutics Ltd (NRSN), including its market capitalization and recent stock performance. It notes that relevant data regarding the company's revenue breakdown by business segments and regions have not yet been disclosed. The content suggests that detailed …

Neurosense Therapeutics Ltd (NRSN) Cash Flow

This article provides an analysis of Neurosense Therapeutics Ltd's (NRSN) cash flow, detailing its operating, investing, and financing activities. It highlights the company's operating cash flow of -7.67M in fiscal 2025 and a 24.31% year-over-year increase, along with capital expenditures of 8.00K and financing …

NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048

This article provides an analysis of Neurosense Therapeutics Ltd (NRSN) including its stock score, financial performance, and risk assessment. TradingKey's comprehensive stock scoring system, which evaluates 34 indicators across six dimensions (financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment), …

TradingKey

This article provides a detailed financial overview of Neurosense Therapeutics Ltd (NRSN) with a focus on its income statement data. It presents quarterly and annual figures for key metrics such as operating expenses, R&D expenses, operating profit, net non-operating interest, income before and after …

NeuroSense Therapeutics (NRSN) Gains 3.08% as Stock Tests Key Resistance at $0.70 - Parabolic SAR

NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug

NeuroSense Therapeutics announced its intent to file a New Drug Submission (NDS) with Health Canada for PrimeC, its lead candidate for amyotrophic lateral sclerosis (ALS). This follows a positive Pre-NDS meeting where updated Phase 2b data, showing a 14.9-month median survival benefit and achievement …

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

NeuroSense Therapeutics announced its intention to file a New Drug Submission (NDS) with Health Canada for PrimeC, its treatment for amyotrophic lateral sclerosis (ALS). This decision follows a constructive pre-NDS meeting and is supported by additional data from the Phase 2b PARADIGM study, which …

NeuroSense Reports 14.9-Month Median Survival Benefit for PrimeC